Hyderabad: Members of the leading Covid-19 task task and health experts who treat patients Coronavirus throughout the country said on Monday that Covid Molnupiravir antivirus drugs reduce hospitalization 30-50%, and the severity of the disease.
A few days after the Head of ICMR Dr.
Balram Bhargava said that Molnupiravir had major health security issues, some Indian top health experts said the benefits of the drug beyond the potential risk.
Studies so far showed convincing side effects among humans, they said.
Late last year, Indian drug regulators, central drug standard control organizations (CDSCO), have approved molnupiravir for limited use in emergency situations.
Read Alsocovid-19: Maharashtra To exclude Molnupiravir for ‘non-komorbidi’ from the new guide the State Health Department has decided to issue a series of new norms after drawing flares to enter new oral anti-virus pills, for “non -comorbid” covid patients in the guidelines Newly revised state care was released on Thursday.
However, the question was raised by the Indian Medical Research Council about its potential to cause teratogenicity, mutagenicity, vulnerable damage, and the possibility of hazards for pregnant and lactating mothers.
“Here are medicines that I believe both CDSCO and DCGI have analyzed before agreeing to use,” said Dr.
Govindarajan Padmanaban, a key member of the National Covid Task Force.
“Anti-viral at this stage is useful, and Molnupiravir must be used to take all precautions because the Covid case is multiplied by dangerous,” he said.
Dr.
Dhruva Chaudhry, Nodal Officer for Covid for Haryana, said so far only research in animals showed some side effects.
“The question is that drugs can cause cancer in humans after using it for only five days? There should be no doubt using drugs among patients over 45-50 years with co-morbidities …” This is a trade-off and more support.
” Dr.
Vasant Nagvestar, a member of the task force, said the drug must be used at the discretion of the doctor.